nach oben

Erschienen in:

11.07.2018 | Original Article

Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil^® or Caelyx^® in advanced ovarian cancer

verfasst von: Shravanti Bhowmik, Subhas Bhowmick, Kuntal Maiti, Amaresh Chakra, Pradeep Shahi, Deepak Jain, Thennati Rajamannar

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the pharmacokinetic bioequivalence and safety of a generic pegylated liposomal doxorubicin formulation (SPIL DXR hydrochloride liposome injection) with that of the reference products, Caelyx or Doxil.

Methods

Two open-label, two-way reference crossover studies were conducted in patients with ovarian cancer. C_max, AUC_0 − t, and AUC_0−∞, V_d, and Cl for total, free, and encapsulated DXR were evaluated in 18 blood samples taken pre-dose (t = 0), at increasing time intervals over the following 14 days. A washout period of 28 days was observed before crossing over.

Results

Studies 1 and 2 were completed by 24/29 and 41/60 patients, respectively. Pharmacokinetic data from 24 patients from each study established bioequivalence for free DXR in study 2, and for total and encapsulated DXR in both studies. Data from 29 and 54 patients, respectively, were included in the safety evaluation. Of these, 37 patients experienced 81 post-dose adverse events (40 related to the test product and 41 related to the reference product). In study 1, four patients were withdrawn owing to adverse events. Eleven patients experienced serious adverse events and one death occurred in study 2.

Conclusions

Bioequivalence between the test and the reference products was established for total and encapsulated DXR in both studies, and for free DXR in the study with the larger sample size (study 2). There were no significant differences between the safety profiles of the generic formulation and the reference products. No correlation was found between drug level and adverse events.

Trial registration

Study 1 was registered retrospectively; registration number is NCT03055143, dated February 15, 2017. Study 2 registration number is NCT00862355, dated March 13, 2009.

Matsumoto K, Onda T, Yaegashi N (2015) Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Jpn J Clin Oncol 45(5):408–410. https://doi.org/10.1093/jjco/hyv014 CrossRefPubMed

Steinherz LJ, Steinherz PG, Tan CC, Heller G, Murphy M (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266(12):1672–1677. https://doi.org/10.1001/jama.1991.03470120074036 CrossRefPubMed

Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, Lipshultz SE (1990) Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116(1):144–147CrossRefPubMed

Benjamin RS, Wiernik PH, Bachur NR (1974) Adriamycin chemotherapy–efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33(1):19–27CrossRefPubMed

Ali SMSS, Ahmad A, Ahmad MU, Chen P, Paithankar M, Choudhury K, Makadia RD, Kumar A, Velavan K, Satheesh CT, Singh JK, Mamillapalli G, Saptarishi D, Kale P, Patel R, Barkate HV, Ahmad I (2016) Bioequivalence study of pegylated doxorubicin hydrochloride liposome (PEGADRIA) and DOXIL® in ovarian cancer patients: physicochemical characterization and pre-clinical studies. J Nanomed Nanotechnol 7:361. https://doi.org/10.4172/2157-7439.1000361 CrossRef

Vici P, Colucci G, Giotta F, Sergi D, Filippelli G, Perri P, Botti C, Vizza E, Carpino A, Pizzuti L, Latorre A, Giannarelli D, Lopez M, Di Lauro L (2011) A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res: CR 30:39. https://doi.org/10.1186/1756-9966-30-39 CrossRefPubMed

Broder H, Gottlieb RA, Lepor NE (2008) Chemotherapy and cardiotoxicity. Rev Cardiovasc Med 9(2):75–83PubMedPubMedCentral

Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869–2879. https://doi.org/10.1002/cncr.11407 CrossRefPubMed

Rahman AM, Yusuf SW, Ewer MS (2007) Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2(4):567–583

10.

Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D (2012) Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 1:10–10. https://doi.org/10.1186/2162-3619-1-10 CrossRefPubMedPubMedCentral

11.

van Dalen EC, Michiels EM, Caron HN, Kremer LC (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005006.pub4 CrossRefPubMed

12.

Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB (1989) Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922–5930PubMed

13.

O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440–449CrossRefPubMed

14.

Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22(19):3893–3901. https://doi.org/10.1200/jco.2004.08.157 CrossRefPubMed

15.

Briasoulis E, Pentheroudakis G, Karavasilis V, Tzamakou E, Rammou D, Pavlidis N (2004) Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. Ann Oncol 15(10):1566–1573. https://doi.org/10.1093/annonc/mdh404 CrossRefPubMed

16.

Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19(5):1444–1454CrossRefPubMed

17.

Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S, Schulz CO, Dieing A, Wischnewsky MB, Hauptmann S, Elling D, Possinger K, Flath B (2005) Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Annals Oncol 16(10):1624–1631. https://doi.org/10.1093/annonc/mdi321 CrossRef

18.

Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A (2000) Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m². Ann Oncol 11(8):1029–1033CrossRefPubMed

19.

Tuscano JM, Martin SM, Ma Y, Zamboni W, O’Donnell RT (2010) Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin’s lymphoma xenograft mouse model. Clin Cancer Res 16(10):2760–2768. https://doi.org/10.1158/1078-0432.ccr-09-3199 CrossRefPubMed

20.

Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (2000) Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78(3 Pt 1):369–372. https://doi.org/10.1006/gyno.2000.5921 CrossRefPubMed

21.

Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691–744PubMed

22.

Adams SF, Marsh EB, Elmasri W, Halberstadt S, VanDecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC (2011) A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 123(3):486–491. https://doi.org/10.1016/j.ygyno.2011.08.032 CrossRefPubMedPubMedCentral

23.

Strauss HG, Hemsen A, Karbe I, Lautenschlager C, Persing M, Thomssen C (2008) Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anti-cancer Drugs 19(5):541–545. https://doi.org/10.1097/CAD.0b013e3282fcbbf7 CrossRefPubMed

24.

European Medicines Agency (2010) Caelyx doxorubicin hydrochloride. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000089/human_med_000683.jsp&mid=WC0b01ac058001d124. Accessed 10 July 2018

25.

Barenholz Y (2012) Doxil(R)--the first FDA-approved nano-drug: lessons learned. J Control Release 160(2):117–134. https://doi.org/10.1016/j.jconrel.2012.03.020 CrossRefPubMed

26.

Ait-Oudhia S, Mager DE, Straubinger RM (2014) Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics 6(1):137–174. https://doi.org/10.3390/pharmaceutics6010137 CrossRefPubMedPubMedCentral

27.

Lionberger R (2015) Pharmaceutical science for generic drugs: the science of equivalence. http://www.nipte.org/sites/default/files//documents/Lionberger.pdf. Accessed 23 Sept 2016

28.

Gaspani SM, B (2013) Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx. GaBI J 2(2):60–62CrossRef

29.

Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J (2009) Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 43(10):1583–1597. https://doi.org/10.1345/aph.1M141 CrossRefPubMed

30.

Committee for Human Medicinal Products (CHMP) (2013) Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. London, UK

31.

US Food and Drug Administration (2017) Draft guidance on doxorubicin hydrochloride. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM199635.pdf. Accessed 25 June 2018

32.

US Food and Drug Administration (2001) Guidance for industry. bioanalytical method validation

33.

Committee for Medicinal Products for Human Use (CHMP) (2010) Guideline on the investigation of bioequivalence. London, UK

34.

Bhowmik S, Bhowmick S, Maiti K, Chakra A, Shahi P, Rajamannar T (2017) Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx((R)) in multiple myeloma. Leuk Lymphoma. https://doi.org/10.1080/10428194.2017.1382692 PubMedCrossRef

35.

Burade V, Bhowmick S, Maiti K, Zalawadia R, Jain D, Rajamannar T (2017) Comparative plasma and tissue distribution of Sun Pharma’s generic doxorubicin HCl liposome injection versus Caelyx((R)) (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague-Dawley rats. Cancer Chemother Pharmacol 79(5):899–913. https://doi.org/10.1007/s00280-017-3278-9 CrossRefPubMedPubMedCentral

36.

Burade V, Bhowmick S, Maiti K, Zalawadia R, Ruan H, Thennati R (2017) Lipodox(R) (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx(R) (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models. BMC cancer 17(1):405. https://doi.org/10.1186/s12885-017-3377-3 CrossRefPubMedPubMedCentral

37.

Smith JA, Costales AB, Jaffari M, Urbauer DL, Frumovitz M, Kutac CK, Tran H, Coleman RL (2016) Is it equivalent? Evaluation of the clinical activity of single agent Lipodox(R) compared to single agent Doxil(R) in ovarian cancer treatment. J Oncol Pharm Pract 22(4):599–604. https://doi.org/10.1177/1078155215594415 CrossRefPubMed

Titel: Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer
verfasst von: Shravanti Bhowmik
Subhas Bhowmick
Kuntal Maiti
Amaresh Chakra
Pradeep Shahi
Deepak Jain
Thennati Rajamannar
Publikationsdatum: 11.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3643-3

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil^® or Caelyx^® in advanced ovarian cancer

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors

Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Brazilin induces FOXO3A-dependent autophagic cell death by disturbing calcium homeostasis in osteosarcoma cells

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie